FocalTherics Reports Preliminary Q2 Sales Of $12.7M-$13.2M, Up 34%-39% Year-On-Year

During the second quarter of 2026, the Extracorporeal Shock Wave Lithotripsy (ESWL) and Distribution segments met the criteria to be classified as held for sale under ASC 205-20, Presentation of Financial Statements — Discontinued Operations, and ASC 360-10, Property, Plant, and Equipment, and the Company determined that the planned exit represents a strategic shift that will have a significant effect on the Company’s operations and financial results. Accordingly, the Company’s unaudited financial results as of and for the three and six months ended June 30, 2026 reflect the Company’s ESWL and Distribution operating segments as discontinued operations. The following reflect the Company’s continuing operations (the Company’s HIFU segment) for the second quarter of 2026: Revenue Between $12.7 and $13.2 million, Representing an Increase Between 34% and 39% from the Three Months Ended Jun...